Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13238505 | 0.83 | CHRM2 (0.55) | CHRM2CHRM4ACHE | |
| SCHEMBL5228400 | 0.80 | ACHE (0.60) | SIGMAR1DRD4ACHE | |
| SCHEMBL18848489 | 0.79 | ACHE (0.54) | SIGMAR1DRD4ACHE | |
| SCHEMBL28639634 | 0.79 | ACHE (0.54) | SIGMAR1DRD4ACHE | |
| SCHEMBL8948610 | 0.79 | SIGMAR1 (0.55) | SIGMAR1ACHE | |
| SCHEMBL2953321 | 0.79 | ACHE (0.54) | SIGMAR1DRD4ACHE | |
| SCHEMBL19450643 | 0.78 | ACHE (0.61) | SIGMAR1DRD4ACHE | |
| SCHEMBL11446990 | 0.76 | SIGMAR1 (0.52) | SIGMAR1ACHE | |
| SCHEMBL7651915 | 0.75 | ACHE (0.62) | SIGMAR1DRD4ACHE | |
| SCHEMBL19770184 | 0.75 | ACHE (0.62) | SIGMAR1DRD4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759340-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20090181955-A1 | Antibacterial Agents | MILLER WILLIAM HENRY | 2009-07-16 | — | — | US | disclosed |
| US-7511035-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-03-31 | — | — | US | disclosed |
| US-20080139539-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139539-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | CHRM2 4696/4885CHRM4 4369/4885SIGMAR1 971/4885 |
| US-20090181955-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | CHRM2 4696/4885CHRM4 4369/4885SIGMAR1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.